IPO - BCAL Diagnostics Limited - 16 July 2021 #, page-36

just have a look at the clinical data for both:
From the BCAL website:
"BCAL approach separates control from IDC Stage 1 and Stage 2 using 12 candidate markers and 2 clinical variables with 85% accuracy and 91% sensitivity (Table) and impressive AUC." (area under the curve I think.) BCAL is developing this for breast cancers only at the moment.

BD1 is below:
from bd1 "The study showed that SubB2M can be used to detect all stages of breast cancer from blood samples with 100% specificity and over 95% sensitivity over healthy controls"

I think that BD1 has a justifiably higher market cap because of the multitude of cancers their diagnostics solutions can identify and the best in class sensitivity/ specificity results.